pathdoc3

Exposure to SARS-CoV-2 spike protein is reported to enhance antiphospholipid antibodies (aPL) mainly via molecular mimicry: S1/S2 subunits form phospholipid-like epitopes resembling β2GPI or phosphatidylethanolamine, driving cross-reactive autoantibodies. In infection, aPL (anti-CL, anti-β2GPI, LA) occur in up to 50% of cases (often transient); post-mRNA vaccination, anti-PE titers rise significantly (p=0.008 in one cohort). For NETs: Spike directly induces NETosis in neutrophils via C-type lectin receptors (not TLR4), triggering ROS production, PAD4-mediated histone citrullination, chromatin decondensation, and DNA expulsion. Sera from spike-exposed patients amplify this in vitro, promoting immunothrombosis. Simple version: Spike looks like body fats, so antibodies attack both virus and self (aPL). It activates neutrophils to burst out sticky DNA nets that trap bugs but clog vessels and inflame tissues. These are mechanisms from peer-reviewed studies; clinical outcomes vary and aPL often resolve.

Sure! Scientifically: The active form of vitamin D (1,25-dihydroxyvitamin D) binds the vitamin D receptor (VDR), which directly binds vitamin D response elements in the PD-L1 gene (CD274), driving its transcription and surface expression on human epithelial/tumor and myeloid cells. Simply: Vitamin D ramps up PD-L1—the "brake" protein tumors use to stop T-cells from attacking. In immunotherapy (like anti-PD-1 drugs), this often means better results because the blockers have more targets to disable, unleashing stronger immunity. Clinical data show vitamin D sufficiency or supplementation boosts response rates and progression-free survival in anti-PD-1-treated melanoma.